Searchable abstracts of presentations at key conferences in endocrinology

ea0016p308 | Endocrine tumours | ECE2008

ERCC1 expression in adrenocortical carcinoma: relationship with baseline characteristics and response to platinum-based chemotherapy

Ronchi Cristina L , Sbiera Silviu , Adams Patrick , Kraus Luthgard , Linss Heidi , Wortmann Sebastian , Willenberg Holger , Allolio Bruno , Fassnacth Martin

Adrenocortical carcinoma (ACC) is a malignant tumor with poor prognosis and no established therapy in advanced stage. Cisplatin is the most frequently used cytotoxic drug, but even combined with doxorubicin and etoposid, the response rate is <50%. Recently, it has been demonstrated that the excision repair cross complementing group 1 (ERCC1) plays a relevant role in the DNA repairing process, particularly in the correction of platinum-induced DNA adducts. Accordingly, ERCC...

ea0016p320 | Endocrine tumours | ECE2008

Mitotane induces a concentration-dependent impairment of platelet aggregation in patients with adrenocortical carcinoma

Hahner Stefanie , Eigenthaler Martin , Savvoukidis Theodoros , Johanssen Sarah , Wortmann Sebastian , Koschker Ann-Cathrin , Allolio Bruno , Fassnacht Martin

Standard treatment of adrenocortical carcinoma (ACC) comprises adrenolytic therapy with mitotane. Prolongation of bleeding time has previously been observed based on a series of 7 patients (Haak et al. 1991). As patients with ACC frequently undergo surgery for local recurrence or metastases, we have studied the effect of mitotane on coagulation in 44 patients with ACC before and/or during treatment with mitotane (total sample size n=62).Pla...

ea0014p139 | (1) | ECE2007

Survivin – a promising target for immunotherapy in patients with adrenocortical carcinoma

Fassnacht Martin , Wortmann Sebastian , Sbiera Silviu , Kuehner Dorothee , Wobser Marion , Adam Patrick , Becker Juergen C. , Allolio Bruno

Objectives: Adrenocortical carcinoma (ACC) is a rare tumor with poor prognosis and limited therapeutic options. Survivin is an anti-apoptotic molecule expressed by neoplastic and tumor-specific endothelial cells of various carcinomas, but rarely or only weakly in normal differentiated tissue. In melanoma and pancreatic cancer, preliminary results of a survivin vaccination trial ( indicated that an immunological response in patients is often paralleled by...

ea0020p182 | Endocrine tumours and neoplasia | ECE2009

Endocrine gland-derived vascular endothelial growth factor and its receptors in adrenocortical carcinoma

Sbiera Silviu , Kuehner Dorothee , Wortmann Sebastian , Adam Patrick , Voelker Hans-Ullrich , Kraus Luitgard , Beyer Melanie , Quinkler Markus , Willenberg Holger , Weismann Dirk , Hahner Stefanie , Allolio Bruno , Fassnacht Martin

Objectives: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF; also termed prokineticin-1) has been identified as a mitogen preferable for the endothelium of steroidogenic glands (1). EG-VEGF and its receptors (prokineticin receptors 1 and 2; PKR1 and 2) are highly expressed in the normal adrenal gland and an autocrine mitogenic loop has been proposed (2). Therefore, we investigated the expression of EG-VEGF and its receptors in adrenocortical carcinoma (ACC)...

ea0016p333 | Endocrine tumours | ECE2008

Deficits in the clinical management of patients with adrenocortical carcinoma in Germany

Johanssen Sarah , Koschker Ann-Cathrin , Hahner Stefanie , Quinkler Marcus , Saeger Wolfgang , Morcos Michael , Willenberg Holger , Langer Peter , Klose Silke , Reisch Nicole , Beuschlein Felix , Brauckhoff Michael , Fottner Christian , Wortmann Sebastian , Oelkers Wolfgang , Maeder Uwe , Fassnacht Martin , Allolio Bruno

Adrenocortical carcinoma (ACC) is a rare disease with poor prognosis. Accordingly, in many cases, the attending doctors have no previous experience with the disease. The aim of our study was to evaluate the quality of care in a large number of patients with ACC in Germany. Data from 263 adult patients of the German ACC registry were analyzed with regard to the following parameters: time to diagnosis, hormonal assessment, imaging, histopathological documentation, follow-up. The...

ea0016p312 | Endocrine tumours | ECE2008

Prognostic factors in localized adrenocortical carcinoma (ACC) after complete resection

Obracay Jens , Fassnacht Martin , Saeger Wolfgang , Johanssen Sarah , Marcus Quinkler , Linden Tobias , Ann-Kathrin Koschker , Sebastian Wortmann , Morcos Michael , Willenberg Holger , Langer Peter , Behrend Matthias , Klose Silke , Reisch Nicole , Brauckhoff Michael , Petersenn Stephan , Bucsky Peter , Oelkers Wolfgang , Maeder Uwe , Hahner Stefanie , Allolio Bruno

Even after complete resection, patients with ACC have a high risk of relapse, and adjuvant treatment with mitotane is frequently recommended. Although mitotane has significant efficacy in this setting, it is associated with a wide range of side effects. As survival is highly variable, prognostic factors are of great interest to better guide adjuvant therapy after radical resection.We analyzed clinical and histopathological data of patients without distan...